Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay

Journal of Pharmaceutical and Biomedical Analysis

Volumn 91, Issue , 2014, Pages 17-23

  Lee, Eunyoung ^a   Eom, Ji Eun ^a   Jeon, Kyung Hwa ^a   Kim, Tae Hee ^a   Kim, Eunnam ^a   Jhon, Gil Ja ^a   Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

Author keywords

96 Well volume reaction; Albumin conformational change; Cobalt albumin binding (CAB) assay; Nitrogen monoxide

Indexed keywords

COBALT; HUMAN SERUM ALBUMIN;

ACCURACY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COBALT ALBUMIN BINDING ASSAY; CONTROLLED STUDY; INTERMETHOD COMPARISON; MEASUREMENT ACCURACY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SENSITIVITY ANALYSIS;

96-WELL VOLUME REACTION; ALBUMIN CONFORMATIONAL CHANGE; COBALT ALBUMIN BINDING (CAB) ASSAY; NITROGEN MONOXIDE;

ALBUMINS; BIOLOGICAL ASSAY; CHEMISTRY, PHARMACEUTICAL; COBALT; INJECTIONS; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY;

EID: 84892473600     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.12.003     Document Type: Article

References (45)

1. Peters T. All About Albumin: Biochemistry, Genetics and Medical Applications 1996, Academic Press, San Diego, London.
2. Neel D.R., McClave S., Martindale R. Hypoalbuminemia in the perioperative period: clinical significance and management options. Best Pract. Res. Clin. Anaesthesiol. 2011, 3:395-400.
3. Dugaiczyk A., Law S.W., Dennison O.E. Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc. Natl. Acad. Sci. USA 1982, 79:71-75.
4. Kragh-Hansen U., Watanabe H., Nakajou K., Iwao Y., Otagiri M. Chain length-dependent binding of fatty acid anions to human serum albumin studied by site-directed mutagenesis. J. Mol. Biol. 2006, 363:702-712.
5. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
6. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P. Human serum albumin: from bench to bedside. Mol. Aspects Med. 2012, 33:209-290.
7. Vincent J.-L., Dubois M.-J., Navickis R.J., Wikes M.M. Hypoalbuminemia in acute illness: is there a rationale for intervention?. Ann. Surg. 2003, 237:319-334.
8. Ryan A.M., Hearty A., Prichard R.S., Cunningham A., Rowley S.P., Reynolds J.V. Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. J. Gastrointest. Surg. 2007, 11:1355-1360.
9. Kobayashi N., Nagai H., Yasuda Y., Kanazawa K. The early influence of albumin administration on protein metabolism and wound healing in burned rats. Wound Rep. Reg. 2004, 12:109-114.
10. Nihei T., Miura Y., Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci. 2001, 68:2845-2852.
11. Vlahos A.L., Crawford R.S., Matthew H.T., Ledgerwood A.M., Lucas C.E. Effect of albumin and hespan on rodent hepatocyte function after hemorrhagic shock and sepsis. J. Trauma 2005, 59:583-588.
12. Gerety R.J., Aronson D.L. Plasma derivatives and viral hepatitis. Transfusion 1982, 22:347-351.
13. 1H-NMR relaxometric study. Biophys. Chem. 2007, 129:29-35.
14. Ueno Y., Mio M., Sato C., Mio K. Single particle conformations of human serum albumin by electron microscopy. J. Electron Microsc. 2007, 56:103-110.
15. Atmeh R.F., Arafa I.M., Al-Khateeb M. Albumin aggregates: hydrodynamic shape and physico-chemical properties. Jor. J. Chem. 2007, 2:169-182.
16. Kshirsagar B., Wilson B., Wiggins R.C. Polymeric complexes and fragments of albumin in normal human plasma. Clin. Chim. Acta 1984, 143:265-273.
17. Dash S., Rao K.V., Hoshi B., Nayak N.C., Panda S.K. Significance of natural polymerized albumin and its receptor in hepatitis B infection of hepatocytes. Hepatology 1991, 13:134-142.
18. Pulimood T.B., Park G.R. Debate: albumin administration should be avoided in the critically ill. Crit. Care 2000, 4:151-155.
19. Gaze D.C. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab. Pharmacokinet. 2009, 24:333-341.
20. Morrow D.A., de Lemos J.A., Sabatine M.S., Antman E.M. The search for a biomarker of cardiac ischemia. Clin. Chem. 2003, 49:537-539.
21. Bar-Or D., Winkler J.V., VanBenthuysen K., Harris L., Lau E., Hetzel F.W. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am. Heart J. 2001, 141:985-991.
22. ® Plus analyzer. Clin. Chem. Lab. Med. 2004, 42:455-461.
23. Christenson R.H., Duh S.H., Sanhai W.R., Wu A.H.B., Holtman V., Painter P., Branham E., Apple F.S., Murakami M., Morris D.L. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin. Chem. 2001, 47:464-470.
24. Roy D., Quiles J., Sinha M., Aldama G., Gaze D., Kaski J.C. Effect of direct-current cardioversion on ischemia-modified albumin levels in patients with atrial fibrillation. Am. J. Cardiol. 2004, 93:366-368.
25. Sinha M.K., Gaze D.C., Tippins J.R., Collinson P.O., Kaski J.C. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003, 107:2403-2405.
26. Bar-Or D., Lau E., Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J. Emerg. Med. 2000, 19:311-315.
27. II-binding site in human serum albumin is not at the N-terminus: implication on the albumin cobalt binding test for detecting myocardial ischemia. Biochemistry 2007, 46:2267-2274.
28. Sokolowska M., Wszelaka-Rylik M., Poznański J., Bal W. Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II) ions in human serum albumin. J. Inorg. Biochem. 2009, 103:1005-1013.
29. Bar-Or D., Bar-Or R., Rael L.T., Gardner D.K., Slone D.S., Craun M.L. Heterogeneity and oxidation status of commercial human albumin preparation in clinical use. Crit. Care Med. 2005, 33:1638-1641.
30. Bar-Or D., Rael L.T., Bar-Or R., Slone D.S., Mains C.W., Rao N.K.R., Curtis C.G. The cobalt-albumin binding assay: insights into its mode of action. Clin. Chim. Acta 2008, 387:120-127.
31. Shim J.H., Lee Y. Amperometric nitric oxide microsensor based on nanopore-plantinized platinum: the application for imaging NO concentrations. Anal. Chem. 2009, 81:8571-8576.
32. Creighton T.E. Electrophoretic analysis of the unfolding of proteins by urea. J. Mol. Biol. 1979, 129:235-264.
33. Das A., Mukhopadhyay C. Urea-mediated protein denaturation: a consensus view. J. Phys. Chem. B 2009, 113:12816-12824.
34. Aljhnia R., Ibrahima F., Guillaumea Y.C., Andre C. Reactive oxygen species and nitric oxide effect on the steroid hormone binding with serum albumin. J. Pharm. Biomed. Anal. 2012, 62:129-134.
35. Schagger H., Cramer W.A., Vonjagow G. Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal. Biochem. 1994, 217:220-230.
36. Niepmann M., Zheng J. Discontinuous native protein gel electrophoresis. Electrophoresis 2006, 27:3949-3951.
37. Goldenberg D.P., Creighton T.E. Gel electrophoresis in studies of protein conformation and folding. Anal. Biochem. 1984, 138:1-18.
38. Salzano A.M., D'Ambrosio C., Scaloni A. Mass spectrometric characterization of proteins modified by nitric oxide-derived species. Methods Enzymol. 2008, 440:3-15.
39. Meurs H., Maarsingh H., Zaagsma J. Encyclopedia of Respiratory Medicine 2006, 161-169. Academic Press, San Diego. G.F. Laurent, S.D. Shapiro (Eds.).
40. Huntington J.A., Stein P.E. Structure and properties of ovalbumin. J. Chromatogr. B 2001, 756:189-198.
41. Goux W.J., Venkatasubramanian P.N. Metal ion binding properties of hen ovalbumin and S-ovalbumin: characterization of the metal ion binding site by phosphorus-31 NMR and water proton relaxation rate enhancements. Biochemistry 1986, 25:84-94.
42. Ascenzi P., Bocedi A., Notari S., Menegatti E., Fasano M. Heme impairs allosterically drug binding to human serum albumin Sudlow's site I. Biochem. Biophys. Res. Commun. 2005, 334:481-486.
43. Yamasaki K., Maruyama T., Yoshimoto K., Tsutsumi Y., Narazaki R., Fukuhara A., Kragh-Hansen U., Otagiri M. Interactive binding to the two principal ligand binding sites of human serum albumin: effect of the neutral-to-base transition. Biochim. Biophys. Acta 1999, 1432:313-323.
44. Baltanás F.C., Weruaga E., Valero J., Recio J.S., Alonso J.R. Albumin attenuates DNA damage in primary-cultured neurons. Neurosci. Lett. 2009, 450:23-26.
45. U.S.Food and Drug Administration Summary basis for regulatory action-albumin (human) 2011, http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM211622.pdf.